NBP
NovaBridge BiosciencesHealthcare · $159M market cap
Verdict
We can't put a fair value on NBP right now. The financial data we receive for it contains an obvious error (its cash-flow profit is more than 10× its reported profit for the same year). We'll value it once the data is corrected.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow NBP
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 3, 2026: no open-market purchases, 1 sale worth $80K and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
Cao Sean Wuxiong
Chief Bus. Development Officer · 2026-09-03
Option exercise
45,320 shares
Cao Sean Wuxiong
Chief Bus. Development Officer · 2026-09-03
Option exercise
102,233 shares
Cao Sean Wuxiong
Chief Bus. Development Officer · 2026-09-03
Option exercise
104,236 shares
Cao Sean Wuxiong
Chief Bus. Development Officer · 2026-09-03
Option exercise
235,136 shares
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works